




RealRate

PHARMACEUTICAL 2021

Zynerba Pharmaceuticals Inc.
Rank 312 of 409



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai

The relative strengths and weaknesses of Zynerba Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Zynerba Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 126% points. The greatest weakness of Zynerba Pharmaceuticals Inc. is the variable Net Income, reducing the Economic Capital Ratio by 215% points.

The company's Economic Capital Ratio, given in the ranking table, is -330%, being 25% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	73,366
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	13,913
Liabilities, Non-Current	0
Other Assets	105
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	0
Property and Equipment	585
Research and Development	35,655
Revenues	0
Selling, General and Administrative Expense	16,408

Output Variable	Value in 1000 USD
Assets	74,057
Liabilities	13,913
Expenses	52,063
Stockholders Equity	60,144
Net Income	-52,063
Comprehensive Net Income	-52,063
Economic Capital Ratio	-330%